• Elastagen

  Participated · Series B · Jan 2016

  Elastagen is a Sidney, Australia-based clinical-stage medical company developing products based on a proprietary recombinant human tropoelastin platform technology. The company applies that platform to three main product areas: atrophic scars (including stretch marks and acne scars), derm-aesthetics, and tissue repair. Its lead programs include an intradermal tropoelastin implant to reduce the appearance of stretch marks, a skin-rejuvenation injectable to improve the skin’s physical properties, and a tropoelastin product to support repair of full-thickness skin wounds. Elastagen is set to initiate a clinical trial to evaluate the safety and efficacy of the intradermal implant for stretch marks. The wound-repair program has had support from the Wellcome Trust and the NSW Department of Health Medical Device Fund. The company closed an A$13M Series B to advance its lead products through clinical and commercial milestones.

• Brickell Biotech

  Led · Series B · Feb 2013

  Brickell Biotech is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics for skin diseases. Its pipeline includes BBI-4000 (a topical soft anticholinergic for primary axillary hyperhidrosis), BBI-5000 (a once-daily oral candidate for moderate to severe atopic dermatitis acquired in January 2015), and BBI-2111 (a first-in-class topical anti-inflammatory for mild to moderate atopic dermatitis). Following an IND submission to the FDA in December 2014, the company initiated a randomized, double-blind, vehicle-controlled 180-patient Phase 2b trial of BBI-4000. The company reported positive results from a prior randomized, double-blind, vehicle-controlled pilot study of BBI-4000 and plans additional clinical testing for BBI-5000 later in the year. Brickell intends to use recent financing to support growth and continued development of its pipeline toward regulatory approval and commercialization. The company is based in Miami and emphasizes rapid, cost-effective development and strategic partnerships. Brickell Biotech is a development-stage pharmaceutical company that acquires, develops and aims to commercialize innovative drug therapies for dermatology. Its pipeline includes new chemical entities targeting acne, atopic dermatitis, and hyperhidrosis. The company emphasizes rapid, cost-effective development of product candidates, strategic partnerships, and a diversified portfolio addressing unmet medical needs. Brickell leverages relationships with thought leaders and contract research organizations and is led by a team with prior drug-development exits and dermatology experience. The Series B financing will support advancing novel compounds from pre-clinical proof of concept through clinical testing.

No current team members are available.